A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jeffrey Gelfand
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Gelfand
Dr. Gelfand is a Professor of Neurology at UCSF. He specializes in caring for patients with a wide range of neuroinflammatory and neurodegenerative disorders. Dr. Gelfand conducts clinical research, including clinical trials, focused on advancing new treatments for neuroimmunological diseases and restoring neurological function. Dr. Gelfand is also an award-winning medical educator.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT05503264
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 152 study participants
- Last Updated